Real-world outcomes for patients with pleural mesothelioma: A multisite retrospective cohort study

Asia-Pacific Journal of Clinical Oncology 2024 December [Link] Kar Ven Cavan Chow, Cassie Turner, Brett Hughes, Zarnie Lwin, Bryan Chan Abstract Aim: To evaluate the real-world treatment patterns and outcomes for patients with pleural mesothelioma (PM) in the era of immunotherapy. Methods: This retrospective audit included patients with PM diagnosed within three tertiary referral centers…

Read More

Volatile Organic Compound Analysis of Malignant Pleural Mesothelioma Chorioallantoic Membrane Xenografts

Journal of Breath Research 2024 August 20 [Link] Liam David Little, Sarah E Barnett, Theo Issitt, Sam Bonsall, Vikki Amanda Carolan, K Elizabeth Allen, Laura Margaret Cole, Neil A Cross, Judy M Coulson, Sarah Louise Haywood-Small Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with asbestos exposure. MPM is often diagnosed late, at…

Read More

FK228 suppress the growth of human malignant pleural mesothelioma tumor independent to epithelioid or non-epithelioid histology

Molecular Medicine 2024 May 31 [Link] James Mei-Lin Chan, Yuan-Ching Chang, Hua-Chen Chan, Hsiu-Chuan Chan, Wei-Chin Chang, Liu-Fang Wang, Tung-Hu Tsai, Yu-Jen Chen, Wen-Chien Huang Abstract Human malignant pleural mesothelioma (hMPM) is an aggressive, rare disease with a poor prognosis. Histologically, MPM is categorized into epithelioid, biphasic, and sarcomatoid subtypes, with the epithelioid subtype generally…

Read More

Predictive potential of MRI in differentiating the predominant component in biphasic pleural mesothelioma

European Journal of Radiology 2024 May 26 [Link] Ritu R Gill, William G Richards, Hillary Heiling, Emanuele Mazzola, Yin P Hung, Ravi T Seethamraju, Lucian R Chirieac, Raphael Bueno Abstract Purpose: To assess the potential of apparent diffusion coefficient (ADC) values derived from diffusion weighted (DW) MRI preoperatively to predict the predominant histologic component among…

Read More

Differential expression of DMD transcripts as a novel prognostic biomarker in histologically diverse mesotheliomas

Translational Lung Cancer Research 2024 April 29 [Link] Nancy Alnassar, Jonathan M J Derry, Giuseppe Luigi Banna, Dariusz C Gorecki Abstract Background: The identification of prognostic biomarkers is crucial for guiding treatment strategies in mesothelioma patients. The Duchenne muscular dystrophy (DMD) gene and its specific transcripts have been associated with patient survival in various tumours.…

Read More

Diffuse pleural mesotheliomas with genomic near-haploidization: a newly recognized subset with distinct clinical, histologic, and molecular features

Clinical Cancer Research 2024 April 7 [Link] Soo-Ryum Yang, Gowtham Jayakumaran, Jamal Benhamida, Christopher A Febres Aldana, Rachel Fanaroff, Jason Chang, Erika Gedvilaite, Liliana B Villafania, Jennifer L Sauter, Michael Offin, Marjorie G Zauderer, Marc Ladanyi Abstract Purpose: Diffuse pleural mesotheliomas (DPMs) with genomic near-haploidization (GNH) represent a novel subtype first recognized by the TCGA…

Read More

Methylthioadenosine Phosphorylase and Breast Cancer 1 Protein-Associated Protein 1 as Biomarkers for the Peritoneal Mesothelioma

Cancer Control 2023 January-December [Link] Yue Chen, Xuemei Du, Ying Gao, Heliang Wu, Hongyu Zhao, Yandong Su Abstract Objectives: Combination of Breast Cancer 1 protein-associated protein 1 (BAP1) and methylthioadenosine phosphorylase (MTAP) in the peritoneal mesothelioma (PeM) has yet to be explored. We aim to assess the diagnostic value of combined BAP1 and MTAP to…

Read More

Validation of a Gene Expression Approach for the Cytological Diagnosis of Epithelioid and Biphasic Pleural Mesothelioma on a Consecutive Series

Cancers 2023 November 22 [Link] Rossella Bruno, Anello Marcello Poma, Greta Alì, Agnese Proietti, Alessandro Ribechini, Antonio Chella, Gabriella Fontanini Abstract Cytological diagnosis of pleural mesothelioma (PM) is controversial, even using ancillary markers (BAP1, MTAP and CDKN2A). Here, we aimed to prospectively validate a previously developed 117-gene expression panel for the differential cytological diagnosis of…

Read More

Treatment with tumor-treating fields (TTFields) suppresses intercellular tunneling nanotube formation in vitro and upregulates immuno-oncologic biomarkers in vivo in malignant mesothelioma

eLife 2023 November 13 [Link] Akshat Sarkari, Sophie Korenfeld, Karina Deniz, Katherine Ladner, Phillip Wong, Sanyukta Padmanabhan, Rachel I Vogel, Laura A Sherer, Naomi Courtemanche, Clifford Steer, Kerem Wainer-Katsir, Emil Lou Abstract Disruption of intercellular communication within tumors is emerging as a novel potential strategy for cancer-directed therapy. Tumor-Treating Fields (TTFields) therapy is a treatment…

Read More